Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Compass Therapeutics Inc.(CMPX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CMPX
09/25/2026: CMPX (3-star) is currently NOT-A-BUY. Pass it for now.
Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based oncology treatments, with its primary asset, CTX-009, targeting specific solid tumors. The company's main strength lies in its proprietary multi-specific antibody discovery platform, which offers potential for long-term R&D success. Its growth story centers on successfully navigating clinical trials to secure regulatory approvals or partnerships with larger pharmaceutical firms. However, investors face significant risks, including binary clinical failure, high cash-burn rates, and stiff competition from well-capitalized industry giants. The stock best suits risk-tolerant investors seeking speculative biotech exposure, and developments regarding trial data and capital efficiency should be closely monitored.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to oncology innovation, though growth is speculative. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience significant momentum around clinical trial results and partnership news. |
| Value investor | Weak fit | The lack of earnings and commercialized products makes traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on cash-intensive R&D. |
| Low-risk investor | Weak fit | The high volatility and clinical binary risks make it unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks fluctuate wildly based on trial results and regulatory updates. |
| Valuation risk | High | Without revenue, valuation is highly sensitive to speculative market sentiment. |
| Competition risk (Oncology/Biotech) | High | Large-cap competitors often have superior resources to bring oncology drugs to market. |
| Business quality | Medium | While the platform is scientific, the lack of commercialized revenue limits current business quality. |
| Dividend income | Low / none | Investors should not expect any income from this security. |
| Execution risk | High | Clinical trial execution is the primary driver of success or failure for the business. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 241.53% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 203.50M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 3.8M shares | Beta 0.84 | 52 Weeks Range 1.10 - 6.88 | Updated Date 09/26/2026 |
52 Weeks Range 1.10 - 6.88 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.39 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Advancing antibody candidates through clinical trials for potential licensing or commercialization. | The company is currently burning cash to prove its drugs work; they make money only if they succeed in trials and license or sell the technology. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 40.46M | Price to Sales(TTM) 269.28 |
Enterprise Value 40.46M | Price to Sales(TTM) 269.28 | ||
Enterprise Value to Revenue 109.28 | Enterprise Value to EBITDA -8.92 | Shares Outstanding 180.09M | Shares Floating 132.45M |
Shares Outstanding 180.09M | Shares Floating 132.45M | ||
Percent Insiders 12.46 | Percent Institutions 88.48 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Compass Therapeutics Inc.
Exchange NASDAQ | Headquarters Boston, MA, United States | ||
IPO Launch date 2021-04-05 | CEO & Vice Chairman Dr. Thomas J. Schuetz M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 39 | |
Full time employees 39 | |||
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.